Altitude

Companies

Psychedelic Stocks

Every public company Altitude covers, from small psychedelic drug developers to the big pharma companies buying into the field. Click a company for its financials, trials, patents and our news coverage.

Prices as of market close, Nov 13, 2026. Updated each trading day.

Psychedelic companies

CompanyPriceDay1 MonthMarket capCash
Definium Therapeutics Nasdaq: DFTX · formerly MindMed$32.08 −2.79% −6.36% $4.39B$241M
GH Research Nasdaq: GHRS$19.10 +3.30% +1.54% $1.31B$246M
Compass Pathways Nasdaq: CMPS$9.01 −1.21% −22.46% $1.28B$444M
Helus Pharma Nasdaq: HELP · formerly Cybin$8.87 +0.11% −19.73% $648M—
Bright Minds Biosciences Nasdaq: DRUG$23.11 +1.63% −57.37% $227M—
NRx Pharmaceuticals Nasdaq: NRXP$2.19 −3.95% −19.19% $95.6M$26.7M
Optimi Health Nasdaq: OPTH$2.25 +3.21% −29.47% $12.9M—
Enveric Biosciences Nasdaq: ENVB$1.52 −0.33% +8.99% $6.76M$5.61M
Clearmind Medicine Nasdaq: CMND$4.53 −1.95% −29.44% $2.25M$3.92M
Rhelion Life Sciences CSE: RHEL · formerly Red Light HollandSee quote on CSE ↗—
Entropy Neurodynamics ASX: ENP · formerly Tryp TherapeuticsSee quote on ASX ↗—
Revive Therapeutics CSE: RVVSee quote on CSE ↗—

Big Pharma in psychedelics

CompanyPriceDay1 MonthMarket capCash
Eli Lilly NYSE: LLY$1,443.50 +1.14% +15.33% $1.36T$4.88B
Johnson & Johnson NYSE: JNJ$285.75 +0.79% +12.82% $689B$16.9B
AbbVie NYSE: ABBV$295.03 +0.20% +4.10% $522B$10.8B

Prices are end-of-day closes from Nasdaq, updated after each U.S. trading day. Prices for companies listed only outside the U.S. link to an outside quote. Cash is cash and equivalents from each company's most recent SEC filing.

This is not investment advice. Altitude is a news publication, and nothing here is a recommendation to buy or sell.